What is the efficacy of solifenacin (Vesicare) in the treatment of overactive bladder (OAB) in children?

Updated: Apr 01, 2019
  • Author: Pamela I Ellsworth, MD; Chief Editor: Edward David Kim, MD, FACS  more...
  • Print

In children, solifenacin was superior to placebo in the following ways:

  • Change from baseline to EoT for maximum voided volume – Solifenacin - placebo difference 12 mL (95% CI 0.2-24.0; P=0.046)
  • Daytime maximum voided volume/micturition (DMaxVV) – Difference in adjusted mean change from baseline for solifenacin - placebo 31.9 mL (95% CI 4.3-39.5; P=0.024)
  • Micturition frequency adjusted for total baseline total volume voided (P=0.0028)

In solifenacin-treated children, the most common treatment-related adverse events were constipation, prolonged QT interval (5.5%), and dry mouth (2.7%). In placebo-treated children, they were constipation and prolonged QT interval (both 2.7%). Two serious adverse events (frontal lobe epilepsy and pyelonephritis) were reported in 2 solifenacin-treated children and 3 serious adverse events (lymphadenitis, hypertension, and tachycardia) were noted in placebo-treated children. [39]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!